More than 20 monoclonal antibodies have been approved as therapeutic drugs by the US
Food and Drug Administration, and it is quite likely that the number of approved antibodies …

Abstract The US Food and Drug administration (FDA) has approved several polyclonal
antibody preparations and at least 18 monoclonal antibody preparations (antibodies …

Integrins are heterodimeric, transmembrane receptors that function as mechanosensors,
adhesion molecules and signal transduction platforms in a multitude of biological processes …

Abstract Development of monoclonal antibodies (mAbs) and their functional derivatives
represents a growing segment of the development pipeline in the pharmaceutical industry …

Nonlinear pharmacokinetics and pharmacodynamics may result from several capacity-
limited processes and often represent complicating factors in characterizing the …

Target‐mediated drug disposition (TMDD) is the phenomenon in which a drug binds with
high affinity to its pharmacological target site (such as a receptor) to such an extent that this …

Purpose The aim of this study is to derive and evaluate an equilibrium model of a previously
developed general pharmacokinetic model for drugs exhibiting target-mediated drug …

Introduction: The number of monoclonal antibodies available for clinical use and under
development has dramatically increased in the last 10 years. Understanding their …

Although monoclonal antibodies (mAbs) constitute a major advance in therapeutics, their
pharmacokinetic (PK) and pharmacodynamic (PD) properties are not fully understood …

Models for drugs exhibiting target-mediated drug disposition (TMDD) describe biological
processes in which drug-target binding significantly influences both pharmacodynamics …